Harvard Bioscience Files Q3 2024 10-Q

TL;DR

Harvard Bioscience filed its Q3 2024 10-Q. Check financials.

AI Summary

Harvard Bioscience Inc. reported its Q3 2024 results, with the filing period ending September 30, 2024. The company's fiscal year ends on December 31st. The filing details financial performance and operational updates for the period.

Why It Matters

This filing provides investors with the latest financial performance and operational details for Harvard Bioscience, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.

Key Numbers

• 3.2 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st.)

Key Players & Entities

• HARVARD BIOSCIENCE INC (company) — Filer
• 20240930 (date) — Reporting Period End Date
• 20241108 (date) — Filing Date
• 001-33957 (dollar_amount) — SEC File Number
• 84 OCTOBER HILL RD (company) — Business Address

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value HBIO The Nasdaq Global Ma

Filing Documents

• hbio20240930_10q.htm (10-Q) — 1258KB
• ex_739912.htm (EX-31.1) — 12KB
• ex_739913.htm (EX-31.2) — 13KB
• ex_739914.htm (EX-32.1) — 5KB
• ex_739915.htm (EX-32.2) — 5KB
• hbio20240930_10qimg001.jpg (GRAPHIC) — 5KB
• 0001171843-24-006181.txt ( ) — 6921KB
• hbio-20240930.xsd (EX-101.SCH) — 67KB
• hbio-20240930_def.xml (EX-101.DEF) — 422KB
• hbio-20240930_lab.xml (EX-101.LAB) — 356KB
• hbio-20240930_pre.xml (EX-101.PRE) — 464KB
• hbio-20240930_cal.xml (EX-101.CAL) — 55KB
• hbio20240930_10q_htm.xml (XML) — 1174KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 1 Consolidated Balance Sheets 1 Consolidated Statements of Operations 2 Consolidated Statements of Comprehensive Loss 3 Consolidated Statements of Stockholders' Equity 4 Consolidated Statements of Cash Flows 5 Notes to Unaudited Consolidated Financial Statements 6

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 24

- OTHER INFORMATION

PART II - OTHER INFORMATION 25

Legal Proceedings

Item 1. Legal Proceedings 25 Item1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 25

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 25

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 25

Other Information

Item 5. Other Information 25

Exhibits

Item 6. Exhibits 25

SIGNATURES

SIGNATURES 26 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. HARVARD BIOSCIENCE, INC. CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands, except share and per share data) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 4,569 $ 4,283 Accounts receivable, net 12,831 16,099 Inventories 25,990 24,716 Other current assets 3,401 3,940 Total current assets 46,791 49,038 Property, plant and equipment, net 5,221 3,981 Operating lease right-of-use assets 6,523 4,773 Goodwill 57,439 57,065 Intangible assets, net 12,341 16,036 Other long-term assets 2,924 6,473 Total assets $ 131,239 $ 137,366 Liabilities and Stockholders' Equity Current liabilities: Current portion of long-term debt $ 3,606 $ 5,859 Accounts payable 5,283 5,554 Contract liabilities 3,689 4,508 Other current liabilities 10,173 10,621 Total current liabilities 22,751 26,542 Long-term debt, net 34,252 30,704 Deferred tax liability 707 776 Operating lease liabilities 6,706 4,794 Other long-term liabilities 1,501 1,476 Total liabilities 65,917 64,292 Commitments and contingencies - Note 13 Stockholders' equity: Preferred stock, par value $ 0.01 per share, 5,000,000 shares authorized - - Common stock, par value $ 0.01 per share, 80,000,000 shares authorized: 43,616,621 shares issued and outstanding at September 30, 2024; 43,394,509 shares issued and outstanding at December 31, 2023 436 434 Additional paid-in-capital 235,973 232,435 Accumulated deficit ( 158,028 ) ( 145,605 ) Accumulated other comprehensive loss ( 13,059 ) ( 14,190 ) Total stockholders' equity 65,322 73,074 Total liabilities and stockholders' equity $ 131,239 $ 137,366 See accompanying notes to condensed consolidated financial statements. 1 Table of Contents HARVARD BIOSCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per shar

View Full Filing

View this 10-Q filing on SEC EDGAR